- Report
- January 2026
- 190 Pages
Global
From €3139EUR$3,545USD£2,713GBP
€3488EUR$3,939USD£3,014GBP
- Report
- July 2025
- 120 Pages
Global
From €5269EUR$5,950USD£4,553GBP
- Report
- February 2026
- 250 Pages
Global
From €3976EUR$4,490USD£3,436GBP
- Report
- January 2026
- 180 Pages
Global
From €3139EUR$3,545USD£2,713GBP
€3488EUR$3,939USD£3,014GBP
- Report
- May 2026
- 224 Pages
Global
From €5181EUR$5,850USD£4,477GBP
- Report
- May 2026
- 375 Pages
Global
From €5181EUR$5,850USD£4,477GBP
- Report
- November 2022
- 141 Pages
Global
From €4384EUR$4,950USD£3,788GBP
- Report
- March 2023
- 150 Pages
Global
From €5269EUR$5,950USD£4,553GBP
- Report
- October 2023
- 183 Pages
Global
From €3985EUR$4,500USD£3,444GBP
- Report
- May 2024
- 200 Pages
Global
From €3675EUR$4,150USD£3,176GBP
- Report
- April 2023
- 115 Pages
Global
From €4206EUR$4,750USD£3,635GBP
- Report
- April 2023
- 117 Pages
Global
From €4206EUR$4,750USD£3,635GBP
- Report
- April 2023
- 120 Pages
Global
From €4206EUR$4,750USD£3,635GBP
- Book
- June 2019
North America
Hodgkin Lymphoma (HL) is a type of cancer that affects the lymphatic system, a part of the immune system. It is characterized by the presence of a type of cell called the Reed-Sternberg cell. HL is the most common type of lymphoma in the United States, and is most common in young adults. Treatment for HL typically involves chemotherapy, radiation therapy, and/or stem cell transplantation.
The oncology market for HL is highly competitive, with a number of companies offering treatments and therapies. These include pharmaceutical companies such as AbbVie, Bristol-Myers Squibb, and Merck; biotechnology companies such as Gilead Sciences and Celgene; and medical device companies such as Medtronic and Stryker. Show Less Read more
